Skip to content 
Body weight tells only part of the story.
Two people can weigh exactly the same yet have very different amounts of skeletal muscle, subcutaneous fat, and visceral adipose tissue. This is one reason body composition has become an increasingly important part of personalized metabolic and peptide medicine.
Tesamorelin is a peptide medication that interacts with the body’s growth hormone-releasing pathway and has been clinically studied for its effects on visceral adipose tissue.
But Tesamorelin is not simply a “belly fat peptide,” nor should it be approached as a universal weight-loss treatment.
At The Best Injector in Delray Beach, peptide therapy begins with understanding the individual patient’s medical history, body composition, goals, medications, relevant laboratory findings, and overall clinical picture.
Not all body fat is the same.
Subcutaneous fat is the fat located directly beneath the skin. Visceral adipose tissue is stored deeper within the abdominal cavity around internal organs.
Although both contribute to overall body composition, they are biologically different types of fat.
This distinction also helps explain why body weight—or even BMI—does not provide a complete picture of an individual’s body composition.
Someone may lose weight without knowing how much of that change came from body fat versus lean mass. Conversely, meaningful changes in body composition may occur even when the number on the scale changes relatively little.
For patients interested in metabolic health, weight management, or peptide therapy, looking beyond total weight can therefore provide a more complete picture.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, commonly abbreviated GHRH.
GHRH is involved in signaling the pituitary gland to release growth hormone. Tesamorelin interacts with this pathway, stimulating endogenous growth hormone secretion and subsequently influencing insulin-like growth factor-1, or IGF-1.
This is different from directly administering growth hormone.
Tesamorelin’s relationship with growth hormone signaling and body composition has made it an area of interest within peptide and metabolic medicine.
Tesamorelin has been clinically studied for its effects on visceral adipose tissue.
Research involving Tesamorelin has demonstrated reductions in visceral abdominal fat within the specific patient populations in which the medication has been formally studied.
This distinction matters because visceral fat is different from the subcutaneous fat immediately beneath the skin.
It also means Tesamorelin should not be thought of as a cosmetic fat-dissolving injection or as a medication designed to selectively sculpt the abdomen.
Instead, it is a medication that affects the growth hormone-releasing pathway and has demonstrated effects on visceral adipose tissue within established clinical research.
The potential relevance of those effects for an individual patient requires medical evaluation rather than assuming that every person concerned about abdominal fat is an appropriate candidate.
Tesamorelin should not be confused with medications specifically intended for chronic weight management.
A reduction in visceral adipose tissue and a reduction in total body weight are not the same thing.
This is an important concept because patients frequently use the terms “fat loss” and “weight loss” interchangeably, even though changes in body composition can occur without substantial changes in overall body weight.
For someone primarily interested in significant weight reduction, an evidence-based medical weight-management strategy may be more appropriate.
Patients whose goals are more specifically related to body composition require a different assessment.
Tesamorelin, semaglutide, and tirzepatide should not be considered interchangeable treatments.
Semaglutide and tirzepatide affect incretin-related pathways involved in appetite, glucose regulation, gastric emptying, and weight management.
Tesamorelin instead acts through the growth hormone-releasing hormone pathway.
This means the choice between these therapies should not be based simply on which medication is receiving the most attention.
A patient’s goals, current body composition, medical history, medications, metabolic profile, contraindications, and treatment priorities all help determine which approach may be most appropriate.
For some patients, the primary objective may be overall weight reduction. For others, maintaining lean mass or understanding changes in body composition may be an important part of the treatment discussion.
A standard scale cannot tell you whether your weight is coming from skeletal muscle, body fat, water, or other components.
That becomes particularly important when evaluating changes in metabolic health and body composition.
At The Best Injector, InBody 570 body composition analysis can provide measurements including skeletal muscle mass, body fat, visceral fat, and other body-composition metrics.
When clinically appropriate, these measurements can help establish a baseline and provide a more objective way to follow changes over time.
This does not mean that every patient receiving peptide therapy requires InBody testing. Rather, it is one of the tools that may be incorporated when body composition is relevant to the patient’s treatment goals.
Yes, although its approved indication is specific.
Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved for general weight-loss management.
When Tesamorelin is considered outside of its approved indication, the decision requires individualized medical evaluation and consideration of the available evidence, potential risks, alternatives, and patient-specific factors.
This is why the regulatory status of a medication and the reason an individual patient is considering treatment are both important parts of the consultation.
Tesamorelin and CJC-1295 + Ipamorelin are all discussed within peptide medicine, but they are distinct therapies.
Tesamorelin and CJC-1295 interact with the growth hormone-releasing hormone pathway, while Ipamorelin primarily acts through the ghrelin receptor as a growth hormone secretagogue.
Their clinical evidence, regulatory status, and potential applications also differ.
For this reason, choosing a peptide should not involve simply selecting one from a list based on its most popular online benefit.
A medical evaluation can help determine whether a particular peptide—or an entirely different treatment strategy—better aligns with the patient’s goals.
There is no universal profile of a patient who should receive Tesamorelin.
A consultation may be appropriate for someone who wants to better understand peptide therapy, body composition, visceral adipose tissue, or the differences between Tesamorelin and other metabolic treatment options.
Whether treatment should actually be recommended depends on factors including:
• Medical history
• Current medications and supplements
• Treatment goals
• Body composition
• Relevant laboratory findings
• Potential contraindications
• Risk factors
• Available clinical evidence
At The Best Injector, the consultation is designed to determine the most appropriate strategy rather than to prescribe a predetermined peptide protocol.
Interest in peptide therapy has grown rapidly, but popularity alone is not a reason to use a particular medication.
At The Best Injector, Lianne Hahn, PA-C evaluates peptide therapy within the larger context of metabolic health, body composition, medical weight management, and the patient’s individual goals.
Depending on the patient, the appropriate recommendation may involve Tesamorelin, another peptide therapy, medical weight management, body-composition monitoring, or no peptide therapy at all.
The objective is not to follow trends. It is to identify the strategy that makes the most clinical sense for the person being treated.
Tesamorelin has been clinically studied for its effects on visceral adipose tissue, which is the deeper abdominal fat surrounding internal organs. Visceral fat is different from subcutaneous fat located directly beneath the skin.
Not exactly. “Belly fat” is an informal term that may refer to several types of abdominal fat. Visceral adipose tissue is specifically the deeper fat located within the abdominal cavity around internal organs.
Not necessarily. Changes in body composition and changes in total body weight are related but are not the same measurement. This is one reason evaluating body composition can provide information that a scale alone cannot.
No. Tesamorelin is a GHRH analog that acts through the growth hormone-releasing pathway. GLP-1 and related medications affect different physiological pathways involved in appetite, glucose regulation, gastric emptying, and weight management.
InBody 570 body composition analysis provides a visceral-fat measurement along with skeletal muscle mass, body fat, and other body-composition metrics that may be useful for establishing a baseline and monitoring changes when clinically appropriate.
No. Abdominal fat alone does not determine whether Tesamorelin is medically appropriate. Treatment decisions should consider the patient’s medical history, body composition, goals, risk factors, contraindications, and available evidence.
Patients interested in learning whether Tesamorelin may be appropriate can learn more about Tesamorelin peptide therapy in Delray Beach or schedule an individualized consultation at The Best Injector.
Visceral fat, body weight, and overall body composition are related—but they are not interchangeable.
Tesamorelin’s effects on the growth hormone-releasing pathway and its clinical research involving visceral adipose tissue have made it an important topic within peptide medicine. That does not mean it is the right treatment for every patient concerned about abdominal fat or weight.
At The Best Injector, treatment begins with understanding the individual.
For patients in Delray Beach, Boca Raton, and surrounding South Florida communities, a personalized consultation can help determine whether Tesamorelin, another peptide therapy, medical weight management, body-composition monitoring, or a different strategy makes the most sense.
Medical Disclaimer: This article is for educational purposes only and does not provide individualized medical advice. Tesamorelin has a specific FDA-approved indication and is not FDA-approved for general weight-loss management. Uses outside of its approved indication require individualized medical evaluation. Treatment recommendations are made only after appropriate assessment of the individual patient.
Lianne evaluates medical history, body-composition concerns, and treatment eligibility before discussing whether tesamorelin may have an appropriate role in an individualized wellness plan.
Lianne Hahn, PA-C is an NCCPA board-certified Physician Assistant and founder of The Best Injector, a boutique medical aesthetics and wellness practice in Delray Beach, Florida. With more than 13 years of clinical experience across aesthetics, dermatology, primary care, medical weight management, and wellness, Lianne combines advanced clinical knowledge with an individualized approach to patient care.
At The Best Injector, Lianne personally evaluates and treats patients from Delray Beach, Boca Raton, Palm Beach County, and throughout South Florida. Her practice offers advanced injectable aesthetics, facial balancing, medical weight management, GLP-1 treatment when clinically appropriate, InBody 570 body composition analysis, microneedling, regenerative treatments, and personalized wellness services.
Lianne’s approach emphasizes appropriate patient selection, individualized treatment planning, natural-looking aesthetic outcomes, and evidence-informed medical care rather than one-size-fits-all treatment protocols.
Author & Medical Reviewer: Lianne Hahn, PA-C
Credentials: NCCPA Board-Certified Physician Assistant
Clinical Experience: 13+ Years
Practice: The Best Injector | Delray Beach, Florida
Serving: Delray Beach, Boca Raton & South Florida
If you’re considering aesthetic treatment, medical weight management, body composition analysis, or wellness services in Delray Beach or Boca Raton, schedule a personalized consultation with Lianne Hahn, PA-C at The Best Injector to determine which treatment options may be appropriate for your individual goals.
This article is intended for educational purposes only and does not replace individualized medical evaluation, diagnosis, or treatment. Treatment eligibility, recommendations, risks, and expected outcomes vary by patient.
